BRD7 and metastatic melanoma: To do so, we first assessed whether TP-472 target BRD7/9 are overexpressed in metastatic melanoma patient samples in the Riker melanoma dataset [14] and associated with advanced disease stage (stage III) in the Xu melanoma dataset [15].